

NEW INFORMATION
Bismuth in Tablet and Suspension (Pepto-Bismol)

Effective January 3, 2017, bismuth products (Pepto-Bismol) in tablet and suspension form will have a frequency limit. The maximum amount will be 8 tablets per day for 14 days or 120mL per day of the liquid for 14 days. The NIHB Drugs and Therapeutics Advisory Committee recommended the change in listing status following the review of clinical evidence for bismuth. Evidence of efficacy was only found for the treatment of *H. pylori* infection for up to 14 days. Please note that the NIHB Program covers a full range of antibiotics and proton pump inhibitors to treat *H. pylori* infection. A full listing of medications is available at: health.gc.ca/dbl.

Naloxone Reimbursement *REVISED*

NIHB has added naloxone ampules, vials and nasal spray as open benefits. To support access to these naloxone products, NIHB will reimburse these naloxone products when prescribed or recommended under the Pharmacist Initiated Treatment Policy.

The list of open benefit naloxone added to the NIHB Drug Benefit List (DBL) as follows:

Name	DIN/pseudo-DIN
Naloxone 1 mg/mL INJ	02148714
Naloxone 1 mg/mL INJ	02393042
Naloxone kit 3 vials or ampules	09991488
Naloxone Nasal Spray (pDIN USA product)	09991474

Medical Assistance in Dying

The NIHB Medical Assistance in Dying (MAiD) formulary provides coverage for clients eligible for MAiD in accordance with provincial/territorial regulations. Providers billing drugs and medical supplies and equipment (MS&E) for MAiD must call the Drug Exception Centre (DEC) and indicate that they are seeking prior approval (PA) for the MAiD formulary. A copy of the MAiD prescription will be required.

Drugs and MS&E items dispensed for MAiD are not subject to NIHBs Short Term Dispensing (STD) policy and providers may override a dispensing fee reduction by entering **special service code (SSC) 2** in such a circumstance.

Please note: MS&E items required to administer MAiD drugs will **not** require approval by Regional Offices – these items can be billed as a single claim under the pseudo-DIN MS&E for MAiD listed below.

Name*	DIN/pseudo-DIN
ACT-propofol 10 mg/mL injection	02437961
atracurium 10 mg/ mL injection	02236759
cisatracurium besylate 2 mg/ mL injection	02406519
cisatracurium besylate 2 mg/ mL injection	02408805
cisatracurium besylate 2 mg/ mL injection	02408813
lidocaine HCL 20 mg/ mL injection	00436208
magnesium sulfate 500 mg/ mL injection	02139499
MAiD compound oral liquid	88000002
Midazolam 1 mg/ mL injection	02240285
Midazolam 5 mg/ mL injection	02240286
MS&E for MAiD	91500008
phenobarbital injection 120 mg/ml injection	02304090
rocuronium bromide 10 mg/ml injection	02318415

**Items that are on the NIHB DBL and are part of the MAiD protocol can be billed as usual.*

Updates to Extemporaneous Mixture Policy

Back Order Items and Compounding

Providers who are preparing a compound to replace a commercially available product which is on back-order do not require a PA. The claim must be submitted using the corresponding miscellaneous pseudo-DIN. Providers are required to maintain documentation demonstrating the commercially available product was on back-order at the time of dispense.

Compounds with Diclofenac

Compounds with diclofenac as an ingredient require a PA and will be reviewed on a case-by-case basis.

Reminder: the compound must not duplicate a commercially available product.

List of Eligible Bases for Compounds

Uremol and CeraVe have been added as eligible topical compounds only. See below for a complete list of eligible non-medicinal bases:

- Aquaphor
- CeraVe cream/lotion
- Cetaphil
- Cliniderm
- Cocoa Butter
- Cold cream
- Compound tincture of benzoin (Friar's balsam)
- Dermabase
- Dilusol
- Eucerin
- Glaxal Base
- Ihle's paste
- Lanolin
- Lassar's paste
- Lubriderm
- Mineral oil
- Petrolatum (Vaseline)
- Uremol cream/lotion
- Zinc oxide creams/ointments

Powders for compounds

A list of powders for compounding that do not require a PA are now eligible for reimbursement when used to compound topical products.

The following powders are eligible without a PA when mixed with open benefit external lotions, creams or ointments that contain a medicinal ingredient. The powders are not eligible when mixed with the non-medicinal bases (as listed above).

- Menthol (in strengths of 0.5% or greater)
- Camphor (in strengths of 0.5% or greater)

The following powders are also eligible without a PA when mixed with open benefit external lotions, creams or ointments, or with an eligible base:

- Hydrocortisone powder (in strengths greater than 0.5%)
- Salicylic acid powder
- Miconazole powder
- Ketoconazole powder
- Nystatin powder
- Clotrimazole powder
- Sulfur powder
- Bethamethasone powder

New Electronic Version of the Modification to Provider Information Form

Providers can now easily update provider information by using the electronic Modification to Provider Information form that is available on the provider website at [provider.express-scripts.ca/documents/Pharmacy/Forms/English/Modification to Pharmacy and Medical Supplies and Equipment Provider Information Form.pdf](http://provider.express-scripts.ca/documents/Pharmacy/Forms/English/Modification%20to%20Pharmacy%20and%20Medical%20Supplies%20and%20Equipment%20Provider%20Information%20Form.pdf).

Please download and use the new form when submitting any updates to provider information.

REMINDERS

Pseudo-DINs for Extemporaneous Mixtures

As of November 16, 2015 the NIHB Program replaced extemporaneous mixture open-benefit pseudo-DINs 00999999, 00990019, 00999997 and 00999994 with pseudo-DINs that are specific to the mixture being submitted. Providers are therefore no longer to bill using pseudo-DINs 00999999, 00990019, 00999997 and 00999994. The following message will be sent back if using the outdated pseudo-DINs: **DIN/PIN/GP# not a benefit**. If this happens, please visit the DBL for extemporaneous mixtures listed in American Hospital Formulary Service (AHFS) Pharmacologic Therapeutic Classification 92:00.00 (healthyamericans.org/publications/health-system-systeme-sante/nihb-drug-list-2016-liste-medicaments-ssna/index-eng.php?page=33#s11-92) to find the correct pseudo-DIN. For DIN inquiries please contact the Express Scripts Canada Provider Call Centre.

Faxing Claims

In exceptional circumstances when submitting manually is required, pharmacy providers can fax original NIHB claim forms for processing to Express Scripts Canada. If preferred, providers can continue submitting claims by mail.

Electronic claim forms are available at [provider.express-scripts.ca/documents/Pharmacy/Forms/English/NIHB Pharmacy Claim Form.pdf](http://provider.express-scripts.ca/documents/Pharmacy/Forms/English/NIHB%20Pharmacy%20Claim%20Form.pdf). Once completed, forms can be faxed to 1 (888) 249-6098.

If you are not using the electronic claim forms, please ensure all submissions are clear and legible. Express Scripts Canada will notify the provider using the Provider Return Letter and request a resubmission if the fax is illegible.

DIN Authorizations

For DIN authorizations, please contact the Drug Exception Centre (DEC) at 1 (800) 580-0950 rather than Express Scripts Canada.

NIHB Claims Services Provider Website

Providers can easily access NIHB Program information, forms, newsletters and fax broadcasts on the NIHB Claims Services Provider Website. This information is publically available and does not require a login ID or password. Providers can continue to access Express Scripts Canada corporate website or go directly to provider.express-scripts.ca. Please bookmark this address for future reference.

NIHB PROGRAM AND EXPRESS SCRIPTS CANADA CONTACT INFORMATION

EXPRESS SCRIPTS CANADA

Provider Claims Processing
Call Centre

Please have your Provider Number readily available

Inquiries

1 (888) 511-4666

Pharmacy Extended Hours

Monday to Friday:
6:30 a.m. to midnight (ET)
Saturday, Sunday and Statutory Holidays:
8 a.m. to midnight (ET)

MS&E Extended Hours

Monday to Friday:
6:30 a.m. to 8:30 p.m. (ET)
Excluding Statutory Holidays

Pharmacy and MS&E Claims

Mail Pharmacy claims to:

Express Scripts Canada
NIHB Pharmacy Claims
P.O. Box 1353, Station K,
Toronto, ON M4P 3J4

Mail MS&E claims to:

Express Scripts Canada
NIHB MS&E Claims
P.O. Box 1365, Station K,
Toronto, ON M4P 3J4

Fax Pharmacy and MS&E claims to:

Toll Free Fax No.: 1 (888) 249-6098

Pharmacy/MS&E Provider Relations
Department & Provider Agreements

Fax Completed

Pharmacy/MS&E Provider Agreements to:

Toll Free Fax No.: 1 (855) 622-0669

Other Correspondence

Mail to:

Express Scripts Canada
5770 Hurontario St., 10th Floor,
Mississauga, ON L5R 3G5

NIHB PROGRAM PHARMACY BENEFITS

Drug Exception Centre (DEC)

PRIOR APPROVALS

Pharmacy Benefits

1 (800) 580-0950 (English)
1 (800) 281-5027 (French)
Fax No.: 1 (877) 789-4379

Health Canada Regional Offices

PRIOR APPROVALS

MS&E Benefits

Alberta	1 (800) 232-7301
Atlantic	1 (800) 565-3294
Manitoba	1 (800) 665-8507
Northwest Territories/Nunavut/Yukon	1 (888) 332-9222
Ontario	1 (800) 881-3921
Quebec	1 (877) 483-1575
Saskatchewan	1 (866) 885-3933

FIRST NATIONS HEALTH AUTHORITY

PRIOR APPROVALS

British Columbia* (fax number) 1 (888) 299-9222

INQUIRIES

British Columbia* 1 (800) 317-7878

**For First Nation residents in British Columbia only.
For non-residents and Inuit, contact the Alberta region.*

NIHB Forms

Download from the NIHB Claims Services Provider Website or contact the Provider Claims Processing Call Centre.